超重和肥胖人类志愿者补充嗜黏蛋白阿克曼菌:一项概念验证探索性研究
该随机双盲安慰剂对照先导研究纳入40例超重/肥胖胰岛素抵抗志愿者、32例完成试验,评估每日口服1010个嗜黏蛋白阿克曼菌活菌或巴氏灭活菌3个月的安全性与代谢指标。巴氏灭活菌组较安慰剂改善胰岛素敏感性(+28.62±7.02%,P=0.002),降低胰岛素血症(-34.08±7.12%,P=0.006)和血浆总胆固醇(-8.68±2.38%,P=0.02)。
要点
- 每日口服1010个嗜黏蛋白阿克曼菌活菌或巴氏灭活菌3个月安全且耐受良好。
- 巴氏灭活菌较安慰剂改善胰岛素敏感性、降低胰岛素血症和总胆固醇。
- 巴氏灭活菌降低体重、脂肪量和臀围的差异未达统计学显著。
核心结论
- 这项概念验证研究(临床试验号NCT02637115)表明干预安全且耐受良好,补充嗜黏蛋白阿克曼菌可改善多项代谢指标。
研究设计与样本
- 随机、双盲、安慰剂对照先导研究,在超重/肥胖胰岛素抵抗志愿者中开展,纳入40例、32例完成试验。
- 主要终点为安全性、耐受性和代谢参数(胰岛素抵抗、循环脂质、内脏脂肪和体重);次要结局为肠道屏障功能(血浆脂多糖)和肠道菌群组成。
- 单中心研究,每日口服1010个嗜黏蛋白阿克曼菌活菌或巴氏灭活菌,持续三个月。
主要发现
- 与安慰剂相比,巴氏灭活嗜黏蛋白阿克曼菌改善胰岛素敏感性(+28.62±7.02%,P=0.002),降低胰岛素血症(-34.08±7.12%,P=0.006)和血浆总胆固醇(-8.68±2.38%,P=0.02)。
- 与安慰剂组相比,巴氏灭活嗜黏蛋白阿克曼菌补充使体重降低(-2.27±0.92 kg,P=0.091)。
- 与基线相比,巴氏灭活嗜黏蛋白阿克曼菌补充使脂肪量降低(-1.37±0.82 kg,P=0.092)、臀围降低(-2.63±1.14 cm,P=0.091)。
- 补充三个月后,嗜黏蛋白阿克曼菌降低肝功能障碍和炎症相关血液标志物水平,而整体肠道微生物组结构未受影响。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabolic syndrome is characterized by a constellation of comorbidities that predispose individuals to an increased risk of developing cardiovascular pathologies as well as type 2 diabetes mellitus1. The gut microbiota is a new key contributor involved in the onset of obesity-related disorders2. In humans, studies have provided evidence for a negative correlation between Akkermansia muciniphila abundance and overweight, obesity, untreated type 2 diabetes mellitus or hypertension3-8. Since the administration of A. muciniphila has never been investigated in humans, we conducted a randomized, double-blind, placebo-controlled pilot study in overweight/obese insulin-resistant volunteers; 40 were enrolled and 32 completed the trial. The primary end points were safety, tolerability and metabolic parameters (that is, insulin resistance, circulating lipids, visceral adiposity and body mass). Secondary outcomes were gut barrier function (that is, plasma lipopolysaccharides) and gut microbiota composition. In this single-center study, we demonstrated that daily oral supplementation of 1010 A. muciniphila bacteria either live or pasteurized for three months was safe and well tolerated. Compared to placebo, pasteurized A. muciniphila improved insulin sensitivity (+28.62 ± 7.02%, P = 0.002), and reduced insulinemia (-34.08 ± 7.12%, P = 0.006) and plasma total cholesterol (-8.68 ± 2.38%, P = 0.02). Pasteurized A. muciniphila supplementation slightly decreased body weight (-2.27 ± 0.92 kg, P = 0.091) compared to the placebo group, and fat mass (-1.37 ± 0.82 kg, P = 0.092) and hip circumference (-2.63 ± 1.14 cm, P = 0.091) compared to baseline. After three months of supplementation, A. muciniphila reduced the levels of the relevant blood markers for liver dysfunction and inflammation while the overall gut microbiome structure was unaffected. In conclusion, this proof-of-concept study (clinical trial no. NCT02637115 ) shows that the intervention was safe and well tolerated and that supplementation with A. muciniphila improves several metabolic parameters.
引用
- Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019. PMID: 31263284. doi:10.1038/s41591-019-0495-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。